Apex, NC — Polyzen announced today that it has been acquired by Solesis, LLC, an advanced biomaterials company that develops, manufactures and sells critical components and technologies for customers in the medical device, biopharmaceutical and life sciences industries. Solesis is headquartered in Telford, PA with manufacturing facilities in Pennsylvania and North Carolina.
“The acquisition creates meaningful value and opportunity for Polyzen and Solesis’ shared customer base. By combining Polyzen’s polymer science experience in film and coating technologies with Solesis’ market leadership in advanced biomaterials, we can accelerate the development of life sciences solutions to address key challenges faced by our medical device and bioprocessing customers,” commented Nikin and Rubin Shah, Co-CEOs of Polyzen.
“We are thrilled about what this new partnership will mean for our customers going forward,” said Karen West, CEO of Solesis. “Polyzen enhances Solesis’ breadth of polymer-based technologies, know-how and capabilities, all of which will enable us to continue to deliver innovative solutions to our
Based in Apex, NC, Polyzen will operate as a subsidiary of Solesis.
Polyzen was advised by Piper Sandler & Co. and Bagchi Law. Cleary Gottlieb acted as legal counsel to Solesis.
Polyzen, LLC is a leading contract developer and manufacturer of custom medical-grade polymer components and products for the medical device and specialty industrial markets worldwide. With fully equipped facilities in Apex, NC, Polyzen develops concepts from prototype to full-scale production with a variety of technologies and services to meet demanding application and regulatory challenges. Polyzen’s 75,000 sq. ft. facility is fully certified to ISO 9001:2015 and ISO 13485:2016 standards and equipped to handle medical-grade polymer development, processing, and manufacturing. For additional information, please visit our website: www.polyzen.com.
Solesis is a market leader specializing in biomaterials for the life sciences industry. Operating through its subsidiaries — Secant Group and Charter Medical — Solesis develops, manufactures and sells critical components and technologies for customers in the medical device, biopharmaceutical, life sciences, and cell and gene therapy industries. Solesis also innovates on behalf of its customers, including through Secant Group’s patented polymer platform poly(glycerol sebacate) (PGS), which demonstrates unparalleled benefits over traditional polymers currently used for drug delivery and medical device applications. Headquartered in Telford, PA, Solesis employs 360 people across four production facilities located in Pennsylvania and North Carolina. For additional information, please visit our website: www.solesis.com.